

Epiomic Epidemiology Series: Multiple Sclerosis Forecast in 18 Major Markets 2017-2027

<https://marketpublishers.com/r/E111FCEB652EN.html>

Date: December 2016

Pages: 98

Price: US\$ 6,150.00 (Single User License)

ID: E111FCEB652EN

Abstracts

Leukaemia refers to a group of cancers which originate in the bone marrow; they result in the overproduction of abnormal white blood cells. This limits the bone marrow's ability to produce normal and fully mature white blood cells. Leukaemia classification is based on the speed of disease progression and the type of cells involved. The main subtypes are myeloid and monocytic, lymphoid or other; these can then be further subdivided into groups such as 'Acute' or 'Chronic'. Acute and chronic refer to the speed of disease progression. Whereas, myeloid, monocytic and lymphoid refer to the cell type affected.

This report provides the current incidence population for Leukaemia across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Turkey, Mexico, Russia, Argentina, Australia, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Leukaemia have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Leukaemia include:

Haemolytic Anaemia

Diabetes

Frequent infections

Headaches

Cachexia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Able to quantify patient populations in global Leukaemia market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the incidence of the subdivided types of Leukaemia and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on Leukaemia incident population.

Identify sub-populations within Leukaemia which require treatment.

Gain an understanding of the specific markets that have the largest number of Leukaemia patients.

Contents

- Introduction
- Cause of the Disease
- Risk Factors & Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis & Clinical Course
- Key comorbid conditions associated with the disease
- Methodology for quantification of patient numbers
- Top-line prevalence for Multiple Sclerosis
 - Diagnosis certainty
- Features of Multiple Sclerosis patients
 - Multiple Sclerosis Subtype
 - Disability severity
 - Abdominal pain
 - Sleep problems
 - Spasticity
 - Urinary and bladder problems
- Comorbidities in Multiple Sclerosis patients
 - Features of MS patients with relapsing- remitting MS
 - Features of MS patients with Secondary Progressive MS
 - Features of MS patients with Primary Progressive MS
 - Features of MS patients with Primary Relapsing MS
- Abbreviations used in the report
- Other Black Swan Analysis Publications
- Black Swan Analysis Online Patient-Based Databases
- Patient-Based Offering
- Online Pricing Data and Platforms
- References
- Appendix

List Of Figures

LIST OF FIGURES

Demyelination in MS

List Of Tables

LIST OF TABLES

The McDonald criteria

Features and characteristics of the subtypes of MS

Prevalence of Multiple Sclerosis, total (000s)

Prevalence of Multiple Sclerosis, males (000s)

Prevalence of Multiple Sclerosis, females (000s)

Diagnosis Certainty of MS, total (000s)

MS subtype, total (000s)

Disability severity of MS patients, total (000s)

Severity of abdominal pain in MS patients, total (000s)

Severity of sleep problems in MS patients, total (000s)

Degree of Spasticity In MS patients, total (000s)

Nocturia in patients with MS, total (000s)

Activity leakage in MS patients, total (000s)

Urgency leakage in MS patients, total (000s)

MS patients with osteopenia, total (000s)

MS patients with diabetes, total (000s)

MS patients with hyperlipidaemia, total (000s)

MS patients with hypertension, total (000s)

MS patients with persistent bothersome pain, total (000s)

MS patients with RLS, total (000s)

MS patients with bone fractures after 3 yrs, total (000s)

MS current smokers, total (000s)

MS patients with neuropathic pain, total (000s)

MS patients with severe fatigue, total (000s)

RRMS with trigeminal neuralgia, total (000s)

RRMS with Lhermitte's sign, total (000s)

RRMS with dysaesthesia, total (000s)

RRMS with painful muscle spasms, total (000s)

RRMS with back pain, total (000s)

RRMS with migraine, total (000s)

SRMS with trigeminal neuralgia, total (000s)

SPMS with Lhermitte's sign, total (000s)

SPMS with dysaesthesia, total (000s)

SPMS with painful muscle spasms, total (000s)

SPMS with back pain, total (000s)

SPMS with migraine, total (000s)
PPMS with trigeminal neuralgia, total (000s)
PPMS with Lhermitte's sign, total (000s)
PPMS with dysaesthesia, total (000s)
PPMS with painful muscle spasms, total (000s)
PPMS with back pain, total (000s)
PPMS with migraine, total (000s)
PRMS with trigeminal neuralgia, total (000s)
PRMS with Lhermitte's sign, total (000s)
PRMS with dysaesthesia, total (000s)
PRMS with painful muscle spasms, total (000s)
PRMS with back pain, total (000s)
PRMS with migraine, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
USA Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Canada Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Canada Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
France Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
France Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Germany Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Germany Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Italy Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Italy Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Spain Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Spain Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
UK Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
UK Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Turkey Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Turkey Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Australia Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Australia Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Poland Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Poland Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Romania Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Romania Prevalence of Acne Vulgaris by 5-yr age cohort, females (000s)
Russia Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Russia Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Brazil Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)

Brazil Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Mexico Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Mexico Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Argentina Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Argentina Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
Japan Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
Japan Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
India Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
India Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)
China Prevalence of Multiple Sclerosis by 5-yr age cohort, males (000s)
China Prevalence of Multiple Sclerosis by 5-yr age cohort, females (000s)

I would like to order

Product name: Epiomic Epidemiology Series: Multiple Sclerosis Forecast in 18 Major Markets 2017-2027

Product link: <https://marketpublishers.com/r/E111FCEB652EN.html>

Price: US\$ 6,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E111FCEB652EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970